Scleroderma treatment sales will grow through 2036, led by anti-inflammatory scleroderma treatment agents at a 30.0% share in 2026 as the leading drug class segment. The market was valued at USD 1.80 billion in 2025 and is expected to reach USD 3.24 billion by 2036, creating an incremental opportunity of USD 1.34 billion.